The number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients keeps rising in most of the European countries despite the pandemic precaution measures. The current antiviral and anti-inflammatory therapeutic approaches are only supportive, have limited efficacy, and the prevention in reducing the transmission of SARS-CoV-2 virus is the best hope for public health. It is presumed that an effective vaccination against SARS-CoV-2 infection could mobilize the innate and adaptive immune responses and provide a protection against severe forms of coronavirus disease 2019 (COVID-19) disease. As the race for the effective and safe vaccine has begun, different strategies were introduced. To date, viral vector-based vaccines, genetic vaccines, attenuated vaccines, and protein-based vaccines are the major vaccine types tested in the clinical trials. Over 80 clinical trials have been initiated; however, only 18 vaccines have reached the clinical phase II/III or III, and 4 vaccine candidates are under consideration or have been approved for the use so far. In addition, the protective effect of the off-target vaccines, such as Bacillus Calmette-Guérin and measles vaccine, is being explored in randomized prospective clinical trials with SARS-CoV-2-infected patients. In this review, we discuss the most promising anti-COVID-19 vaccine clinical trials and different vaccination strategies in order to provide more clarity into the ongoing clinical trials.

Department of Immunology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czechia

Department of Paediatric and Adult Rheumatology University Hospital Motol Prague Czechia

Zobrazit více v PubMed

Weston S, Frieman MB. COVID-19: knowns, unknowns, and questions. mSphere. 2020;5((2)):e00203–20. PubMed PMC

Hiscott J, Alexandridi M, Muscolini M, Tassone E, Palermo E, Soultsioti M, et al. The global impact of the coronavirus pandemic. Cytokine Growth Factor Rev. 2020;53:1–9. PubMed PMC

Kaur SP, Gupta V. COVID-19 vaccine: a comprehensive status report. Virus Res. 2020;288:198114. PubMed PMC

Strizova Z, Bartunkova J, Smrz D. Can wearing face masks in public affect transmission route and viral load in COVID-19? Cent Eur J Public Health. 2020;28((2)):161–2. PubMed

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38((1)):1–9. PubMed

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9((1)):221–36. PubMed PMC

Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69((3)):379–88. PubMed PMC

Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, et al. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr Biol. 2020;30((11)):2196–203.e3. PubMed PMC

Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci. 2020;16((10)):1678–85. PubMed PMC

Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583((7815)):282–5. PubMed

Johansen MD, Irving A, Montagutelli X, Tate MD, Rudloff I, Nold MF, et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 2020;13((6)):877–91. PubMed PMC

Mallapaty S. COVID mink analysis shows mutations are not dangerous: yet. Nature. 2020;587((7834)):340–1. PubMed

Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nat Commun. 2020;11((1)):6231. PubMed PMC

Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlsein P, Smits SL, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351((6268)):77–81. PubMed

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26((6)):729–34. PubMed PMC

Daoust JF. Elderly people and responses to COVID-19 in 27 Countries. PLoS One. 2020;15((7)):e0235590. PubMed PMC

Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Daily Kirley P, et al. Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2020 Sep 18;:ciaa1419. PubMed PMC

Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11((1)):5493. PubMed PMC

Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2020 PubMed PMC

He J, Ni Y, Liao L, Xiao Y, Guo Y. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. 2021 Feb;93((2)):820–30. PubMed PMC

Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M, et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2) Int J Antimicrob Agents. 2020;56((2)):106080. PubMed PMC

National Library of Medicine at the U.S. National Institutes of Health ClinicalTrials. Available from: www.clinicaltrials.gov.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31((11)):1409–17. PubMed

Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020;5((1)):84. PubMed PMC

Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res Cardiol. 2020;115((3)):31. PubMed PMC

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55((4)):2000607. PubMed PMC

Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020;56((2)):2000763. PubMed PMC

Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020;507:164–6. PubMed PMC

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17((6)):613–20. PubMed PMC

Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52((6)):971–7. PubMed PMC

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181((7)):1489–1501.e15. PubMed PMC

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183((1)):158–68.e14. PubMed PMC

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20((10)):615–32. PubMed PMC

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396((10262)):1595–606. PubMed PMC

Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014;111((34)):12283–7. PubMed PMC

Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines. 2012;11((6)):695–719. PubMed

Zepp F. Principles of vaccine design-lessons from nature. Vaccine. 2010;28((Suppl 3)):C14–24. PubMed

Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers. Vaccines. 2016 Apr 16;4((2)):12. PubMed PMC

Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017;38((9)):771–93. PubMed

Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines. 2015;3((2)):320–43. PubMed PMC

Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89((6)):2995–3007. PubMed PMC

Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012;45((12)):1102–11. PubMed PMC

Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv. 2009;27((4)):449–67. PubMed PMC

Syomin BV, Ilyin YV. Virus-like particles as an instrument of vaccine production. Mol Biol. 2019;53((3)):323–34. PubMed PMC

Hobernik D, Bros M. DNA vaccines-how far from clinical use? Int J Mol Sci. 2018;19((11)):3605. PubMed PMC

Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005;175((2)):633–9. PubMed

Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15((3)):313–29. PubMed PMC

Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin. 2006;2((2)):45–53. PubMed

Ross J. mRNA stability in mammalian cells. Microbiol Rev. 1995;59((3)):423–50. PubMed PMC

Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. PubMed PMC

Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol. 2009;182((11)):6824–33. PubMed

Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol. 2013;10((2)):103–6. PubMed PMC

Kato H, Oh SW, Fujita T. RIG-I-like receptors and type I interferonopathies. J Interferon Cytokine Res. 2017;37((5)):207–13. PubMed PMC

Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21((1)):251–9. PubMed PMC

Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018;26((2)):446–55. PubMed PMC

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov. 2018;17((4)):261–79. PubMed PMC

Ramezanpour B, Haan I, Osterhaus A, Claassen E. Vector-based genetically modified vaccines: exploiting Jenner's legacy. Vaccine. 2016;34((50)):6436–48. PubMed PMC

Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother. 2014;10((10)):2875–84. PubMed PMC

Humphreys IR, Sebastian S. Novel viral vectors in infectious diseases. Immunology. 2018;153((1)):1–9. PubMed PMC

Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963. doi: 10.3389/fimmu.2018.01963. PubMed DOI PMC

Zhang L, Wang W, Wang S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines. 2015;14((11)):1509–23. PubMed PMC

Schnyder JL, De Pijper CA, Garcia Garrido HM, Daams JG, Goorhuis A, Stijnis C, et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination: a systematic review and meta-analysis. Travel Med Infect Dis. 2020 Sep− Oct;37:101868. PubMed PMC

Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu HJ. Mucosal vaccines: strategies and challenges. Immunol Lett. 2020;217:116–25. PubMed

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396((10249)):467–78. PubMed PMC

Voysey M, Clemens SAC, Madhi SA, Weckx LW, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020 Dec 8;397((10269)):99–111. PubMed PMC

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med. 2020;383((20)):1920–31. PubMed PMC

Polack FP, Thomas SK, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383((27)):2603–15. PubMed PMC

Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) Proc Natl Acad Sci U S A. 2020;117((30)):17720–6. PubMed PMC

Kamat S, Kumari M. BCG against SARS-CoV-2: second youth of an old age vaccine? Front Pharmacol. 2020;11:1050. PubMed PMC

Moorlag SJCFM, van Deuren RC, van Werkhoven CH, Jaeger M, Debisarun P, Taks E, et al. Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Rep Med. 2020;1((5)):100073. PubMed PMC

Rajarshi K, Chatterjee A, Ray S. BCG vaccination strategy implemented to reduce the impact of COVID-19: hype or hope? Med Drug Discov. 2020;7:100049. PubMed PMC

Sharma A, Kumar Sharma S, Shi Y, Bucci E, Carafoli E, Melino G, et al. BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? Cell Death Dis. 2020;11((7)):516. PubMed PMC

Anbarasu A, Ramaiah S, Livingstone P. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality? Hum Vaccin Immunother. 2020;16((9)):2217–8. PubMed PMC

Ashford JW, Gold JE, Huenergardt MJA, Katz RBA, Strand SE, Bolanos J, et al. MMR vaccination: a potential strategy to reduce severity and mortality of COVID-19 Illness. Am J Med. 2020 Oct 23;S0002–9343((20)):30902–5. PubMed PMC

Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204((2)):245–52. PubMed

Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25((12)):1473–8. PubMed

Rieckmann A, Villumsen M, Sørup S, Haugaard LK, Ravn H, Roth A, et al. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971–2010. Int J Epidemiol. 2017;46((2)):695–705. PubMed PMC

Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014;311((8)):826–35. PubMed

Abdelrahman Z, Li M, Wang X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses. Front Immunol. 2020;11:552909. PubMed PMC

Lewnard JA, Cobey S. Immune history and influenza vaccine effectiveness. Vaccines. 2018 May 21;6((2)):28. PubMed PMC

Rosendahl Huber SK, Hendriks M, Jacobi RHJ, van de Kassteele J, Mandersloot-Oskam JC, van Boxtel RAJ, et al. Immunogenicity of influenza vaccines: evidence for differential effect of secondary vaccination on humoral and cellular immunity. Front Immunol. 2018;9:3103. PubMed PMC

Christenson B, Böttiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 1994;12((2)):129–33. PubMed

Kongsgaard M, Bassi MR, Rasmussen M, Skjødt K, Thybo S, Gabriel M, et al. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Sci Rep. 2017;7((1)):662. PubMed PMC

Hanley KA. The double-edged sword: how evolution can make or break a live-attenuated virus vaccine. Evolution. 2011;4((4)):635–43. PubMed PMC

Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010;28((6)):573–9. PubMed PMC

Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479–480:379–92. PubMed

Mok DZL, Chan KR. The effects of pre-existing antibodies on live-attenuated viral vaccines. Viruses. 2020 May 8;12((5)):520. PubMed PMC

Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res. 2009;84((2)):119–30. PubMed PMC

Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15((1)):34–41. PubMed PMC

U.S. Food and Drug Administration. Accessed 2020 Dec 11. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.

European Medicines Agency. Accessed 2020 Nov 6. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19.

Milstien J, Costa A, Jadhav S, Dhere R. Reaching international GMP standards for vaccine production: challenges for developing countries. Expert Rev Vaccines. 2009;8((5)):559–66. PubMed

Bonilla FA. Update: vaccines in primary immunodeficiency. J Allergy Clin Immunol. 2018;141((2)):474–81. PubMed

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79((1)):39–52. PubMed

Friedmann D, Goldacker S, Peter H-H, Warnatz K. Preserved cellular immunity upon influenza vaccination in most patients with common variable immunodeficiency. J Allergy Clin Immunol Pract. 2020;8((7)):2332–40. PubMed

Mieves JF, Wittke K, Freitag H, Volk HD, Scheibenbogen C, Hanitsch LG. Influenza vaccination in patients with common variable immunodeficiency (CVID) Curr Allergy Asthma Rep. 2017;17((11)):78. PubMed

Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020;15((8)):630–45. PubMed PMC

Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: a multidisciplinary review. Front Public Health. 2020;8:383. PubMed PMC

Encapsulation: A Strategy to Deliver Therapeutics and Bioactive Compounds?

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

How COVID-19 Affects Lung Transplantation: A Comprehensive Review

Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety